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Introduction
Autophagy is an evolutionarily conserved process involved 
in selective degradation of long-lived proteins and damaged 
organelles.1 Initiation of autophagy begins with the formation 
of nascent autophagosomes, double-membrane vesicles that 
form around cellular components destined for destruction. 
Canonical autophagosome formation involves 4 steps: 1) 
initiation, 2) nucleation, 3) elongation, and 4) closure. Following 
initiation, the PIK3C3/VPS34-BECN1 complex is necessary for 
autophagosome nucleation. PIK3C3 is the catalytic subunit of 
the phosphatidylinositol (PtdIns) 3-kinase (PtdIns3K), which 
belongs to the class III PtdIns3K family, and phosphorylates 
PtdIns to generate PtdIns3P, a lipid second messenger essential 
for autophagosome trafficking.2,3 The interaction between 
BECN1 (the mammalian ortholog of yeast Vps30/Atg6) and 
PIK3C3 is important for the recruitment of autophagy proteins 
to the nucleating phagophore assembly sites (PAS).4 Subsequently, 
autophagosome elongation and closure occur, wherein soluble 
and cleaved LC3-I is conjugated to phosphatidylethanolamine 
*Correspondence to: Qi Zeng; Email: mcbzengq@imcb.a-star.edu.sg; James T Murray; Email: James.Murray@tcd.ie
Submitted: 08/29/2013; Revised: 07/02/2014; Accepted: 07/17/2014; Published Online: 08/01/2014
http://dx.doi.org/10.4161/auto.29989
A role of autophagy in PTP4A3-driven  
cancer progression
Yu-han huang,1,2,† abdul Qader O al-aidaroos,1,† hiu-Fung Yuen,1,† shu-Dong Zhang,3 han-Ming shen,4 ewelina Rozycka,3,‡ 
cian M Mccrudden,3 Vinay Tergaonkar,1 abhishek Gupta,1 You Bin Lin,1 Jean Paul Thiery,1,5 James T Murray,‡,* and Qi Zeng1,5,*
1institute of Molecular and cell Biology; a*sTaR (agency for science, Technology and Research); singapore; 2NUs Graduate school for integrative sciences and engineering; 
National University of singapore; singapore; 3center for cancer Research and cell Biology; Queen’s University Belfast; Belfast UK; 4Department of epidemiology and Public 
health; National University of singapore; singapore; 5Department of Biochemistry; Yong Loo Lin school of Medicine; National University of singapore; singapore
‡current affiliation: school of Biochemistry and immunology; Trinity college; Dublin, ireland
†These authors contributed equally to this work.
Keywords: BECN1, cancer progression, mammalian autophagy regulation, PIK3C3, prognosis marker, PTP4A3
Abbreviations: ATG5, autophagy-related 5; BafA1, bafilomycin A1; BECN1, Beclin 1, autophagy related; CQ, chloroquine;  
EGFP, enhanced green fluorescent protein; MAP1LC3/LC3, microtubule-associated protein 1 light chain 3; GEO: Gene 
Expression Omnibus; HBSS, Hank’s balanced salt solution; HSPD1, heat shock 60 kDa protein 1; KRAS, Kirsten rat sarcoma 
viral oncogene homolog; MTOR, mechanistic target of rapamycin; PAS, phagophore assembly site; PDM: phosphatase-defective 
mutant; PE, phosphatidylethanolamine; PIK3C3, phosphatidylinositol 3-kinase, catalytic subunit type 3;  
PtdIns3P, phosphatidylinositol 3-phosphate; PTP4A3/PRL-3, protein tyrosine phosphatase type IVA, member 3;  
SQSTM1, sequestosome 1; ULK1, unc-51 like autophagy activating kinase 1
autophagy, a “self-eating” cellular process, has dual roles in promoting and suppressing tumor growth, depending 
on cellular context. PTP4a3/PRL-3, a plasma membrane and endosomal phosphatase, promotes multiple oncogenic 
processes including cell proliferation, invasion, and cancer metastasis. in this study, we demonstrate that PTP4a3 
accumulates in autophagosomes upon inhibition of autophagic degradation. expression of PTP4a3 enhances PiK3c3-
BecN1-dependent autophagosome formation and accelerates Lc3-i to Lc3-ii conversion in an aTG5-dependent manner. 
PTP4a3 overexpression also enhances the degradation of sQsTM1, a key autophagy substrate. These functions of PTP4a3 
are dependent on its catalytic activity and prenylation-dependent membrane association. These results suggest that 
PTP4a3 functions to promote canonical autophagy flux. Unexpectedly, following autophagy activation, PTP4a3 serves 
as a novel autophagic substrate, thereby establishing a negative feedback-loop that may be required to fine-tune 
autophagy activity. Functionally, PTP4a3 utilizes the autophagy pathway to promote cell growth, concomitant with the 
activation of aKT. clinically, from the largest ovarian cancer data set (Gse 9899, n = 285) available in GeO, high levels of 
expression of both PTP4a3 and autophagy genes significantly predict poor prognosis of ovarian cancer patients. These 
studies reveal a critical role of autophagy in PTP4a3-driven cancer progression, suggesting that autophagy could be a 
potential achilles heel to block PTP4a3-mediated tumor progression in stratified patients with high expression of both 
PTP4a3 and autophagy genes.
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(PE) to form membrane-bound LC3-II. This process, called 
“LC3 conversion,” requires ATG5 and constitutes a critical step 
for autophagosome maturation.5,6 In contrast, noncanonical 
autophagosome formation can occur independently of some of 
these autophagy proteins or even bypass some of these steps.7 
Mature autophagosomes, carrying all the unwanted cellular 
organelles and autophagy substrate, ultimately fuse with 
lysosomes, where their contents are degraded and recycled to 
release nutrients and energy for de novo biosynthesis of new 
membranes and proteins.1
Generally, autophagy functions as a homeostatic cellular 
recycling mechanism to ensure cellular survival by minimizing 
accumulation of cellular damage and during starvation by 
maintaining cellular energy levels.8 As a consequence of this 
critical role, autophagy is frequently associated with mechanisms 
of cell death, particularly following prolonged autophagy 
activation that results in progressive consumption of cellular 
components.9 Prosurvival and/or prodeath roles for autophagy 
are highly dependent on cellular context, with implications 
in treatment of diseases where autophagy is associated with 
pathology. For example, modulation of autophagy using either 
autophagy activators or inhibitors has both been described to 
have anti-cancer effects.9 Reliable predictors of the consequence 
of a tumor response to autophagy modulation remain poorly 
characterized.
PTP4A3 is a prenylated protein tyrosine phosphatase we 
identified in 1998.10 It is best known for its role in promoting 
cancer metastasis.11 Upregulation of PTP4A3 in metastatic 
specimens from colorectal cancer was reported a decade ago.12 
The oncogenic roles of PTP4A3 overexpression include increased 
cell migration/invasion in vitro, and enhanced metastasis 
in vivo through activation of the Rho GTPase family and 
the phosphoinositide 3-kinase-AKT pathway.13-15 PTP4A3 
also promotes cell proliferation, angiogenesis, and cell-cycle 
progression.16-18 More importantly, PTP4A3 is upregulated in 
clinically malignant cancer specimens compared with their 
benign counterparts in multiple human cancers and is associated 
with poor prognosis.12,16,19,20
Recently, endosomes were shown to play an important 
function in autophagy, fusing with autophagosomes prior to 
lysosomal fusion for cargo degradation.21-23 Since PTP4A3 and its 
close homolog PTP4A1 both have endosomal localization,10,24 we 
investigated whether they were functionally linked to autophagy. 
Here, we report that PTP4A3, but not PTP4A1, has a novel role 
in canonical autophagy. Our results suggest that PTP4A3 is both 
an activator and a substrate of autophagy, providing a possible 
negative feedback mechanism for regulating autophagic flux. 
Notably, we provide new evidence of a critical role for autophagy 
during PTP4A3-mediated ovarian cancer cell growth and 
tumor progression, indicating that elevated PTP4A3 expression 
is a predictive biomarker of antiautophagy therapy for patients 
having high expression of autophagy genes.
Results
PTP4A3, but not PTP4A1, colocalizes with LC3 in 
autophagosomes and promotes LC3 puncta accumulation upon 
chloroquine treatment
PTP4A1 and PTP4A3 are 2 closely related prenylated protein 
phosphatases, sharing 79% amino acid identity.10 Both are localized 
to the cytosolic face of the plasma membrane and endosomes.24 
In light of recent reports suggesting a role for endosomes in 
autophagy,22 we investigated whether PTP4A1 or PTP4A3 
was also localized to nascent autophagosomes. We ectopically 
expressed myc-tagged PTP4A1 and PTP4A3 in Chinese Hamster 
Ovary (CHO) cells (CHO-PTP4A1 and CHO-PTP4A3) 
together with EGFP-tagged LC3, and tracked autophagosome 
formation upon treatment with chloroquine (CQ), a lysosomal 
acidification inhibitor that blocks autophagic degradation. Upon 
CQ treatment, PTP4A1 localization remained largely unchanged 
and poorly colocalized with LC3 puncta (Fig. 1A, b”). In contrast, 
PTP4A3 accumulated and colocalized well with LC3-positive 
puncta-like structures (Fig. 1B, b”). Using another late stage 
autophagy inhibitor, bafilomycin A
1
 (BafA1),25 colocalization 
of PTP4A3 and LC3 puncta was observed as early as 1 h after 
BafA1 treatment (Fig. S1A; Fig. 1B, c’). Such LC3-positive 
puncta have been characterized as a signature of autophagosomes 
and amphisomes (collectively referred to as AP hereafter), 2 types 
of autophagic vacuoles that form prior to lysosomal fusion and 
cargo degradation.26,27 We next examined whether the presence of 
PTP4A3 in AP might implicate a role for PTP4A3 in autophagy 
regulation. We noted that CHO-PTP4A3 cells contained more 
endogenous LC3 puncta per cell compared with CHO control 
(CHO-Con) or CHO-PTP4A1 cells following CQ treatment 
(Fig. 1C). Quantification of LC3 puncta intensity confirmed a 
significantly higher LC3 puncta intensity per cell in CQ-treated 
CHO-PTP4A3 cells compared with either CHO-Con or CHO-
PTP4A1 cells (Fig. 1D; P < 0.001). Collectively, our results 
suggest that upon CQ treatment, ectopically expressed PTP4A3 
colocalizes with LC3 in AP and promotes AP accumulation.
PTP4A3 requires catalytic activity and prenylation-
dependent membrane association to promote AP accumulation 
via the canonical PIK3C3-BECN1 autophagy pathway
To understand the molecular factors regulating PTP4A3 
recruitment into AP, we constructed 3 expression plasmids: 
EGFP-tagged wild-type PTP4A3 (PTP4A3), EGFP-tagged 
PTP4A3 catalytic-dead mutant (Cys104Ser, PDM) or EGFP-
Vector control (Vec), and stably expressed the 3 constructs in 
A2780 human ovarian cancer cells. Upon CQ treatment, we 
noted that A2780-PTP4A3 cells contained more endogenous 
LC3 puncta (Fig. 2A, b’) per cell compared with A2780-Vec 
or A2780-PDM cells following CQ treatment (Fig. 2A, a’ and 
c’). This was despite the PDM mutant still colocalizing with 
AP (Fig. 2A, c”), suggesting that in addition to localization, 
PTP4A3 catalytic activity was also important for enhancing AP 
accumulation. Quantification of LC3 puncta intensity confirmed 
a significantly higher LC3 puncta frequency per cell in A2780-
PTP4A3 cells compared with either A2780-Vec or A2780-PDM 
cells (Fig. 2B; P < 0.01). Prenylation was previously shown to 
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be essential for PTP4A3 plasma membranous and endosomal 
localization.24 We next constructed and ectopically expressed the 
PTP4A3 prenylation mutant (Cys170Ser, PreΔ) in A2780 cells. 
As expected, prenylation-defective PTP4A3 (PreΔ) no longer 
colocalized with LC3 in puncta-like structures nor increased 
cellular LC3 puncta (Fig. S2A, c–c”). Thus, we conclude 
that PTP4A3 phosphatase requires both catalytic activity and 
prenylation-mediated membrane association to promote AP 
accumulation upon CQ treatment.
To address whether PTP4A3 promoted AP accumulation 
via the canonical autophagy pathway upon CQ treatment, we 
stably knocked down PIK3C3 or BECN1—2 critical upstream 
regulators of canonical autophagosome formation28—using gene-
specific shRNAs in A2780-Vec, A2780-PTP4A3 and A2780-
PDM cells (Fig. 2C). In agreement with our earlier observations, 
in the control knockdown group (shScr), significantly more LC3 
puncta accumulated in A2780-PTP4A3 cells, compared with 
A2780-Vec or A2780-PDM cells, upon CQ treatment (Fig. 2D, 
first 3 columns; P < 0.01). Knockdown of either PIK3C3 
(Fig. 2D, middle 3 columns) or BECN1 (Fig. 2D, last 3 columns) 
effectively abolished CQ-induced AP accumulation by PTP4A3 
(P > 0.05, PTP4A3 vs. Vec or PDM). Our data thus suggests 
that PTP4A3 promotes AP formation via the canonical PIK3C3-
BECN1 autophagy pathway.
Figure 1. PTP4a3, but not PTP4a1, colocalizes with Lc3-positive puncta and promotes aP accumulation upon cQ-mediated autophagic degradation 
inhibition. (A and B) chO cells overexpressing myc-PTP4a1 (chO-PTP4a1) (A) or myc-PTP4a3 (chO-PTP4a3) (B) were transfected with eGFP-Lc3 reporter 
construct, and allowed to grow for 24 h. The transfected cells were treated with or without cQ in full media for another 24 h before immunostaining with 
an anti-myc antibody (scale bar: 20 μm). (C) chO control (chO-con), chO-PTP4a1, and chO-PTP4a3 were treated with or without cQ for 24 h prior to 
immunostaining for Lc3 (green) and actin (red). Representative images are shown in the left panel (scale bar: 20 μm). (D) Lc3 puncta intensity of at least 
20 cells from 5 distinct viewing fields were quantified as described in Materials and Methods, and presented as a histogram in the right panel (mean ± 
s.D.). ***P < 0.001.
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Figure 2. For figure legend, see page 1791.
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Rapamycin is an inhibitor of the mechanistic target of 
rapamycin (MTOR), a key cellular kinase regulating autophagy 
in response to physiological conditions and environmental stress.29 
Rapamycin treatment relieves the suppression of autophagy 
by MTOR.30,31 Using a combination treatment of rapamycin 
and CQ, we found that significantly more AP accumulated in 
rapamycin-treated A2780-PTP4A3 cells compared with A2780-
Vec or A2780-PDM cells (P < 0.001; Fig. 2E). This suggests that 
while MTOR inhibition activates autophagy, PTP4A3 activity 
further enhances AP accumulation, potentially revealing a novel 
mechanism whereby PTP4A3 augments canonical autophagy 
signaling downstream of MTOR.
PTP4A3 promotes autophagic flux (LC3-I to LC3-II 
conversion) in an ATG5-dependent manner
To study whether PTP4A3 could activate autophagy, 
immunoblotting was used to detect “autophagic flux” by 
comparing LC3-I to LC3-II conversion in cells either with or 
without CQ treatment. Lipidation of soluble LC3-I converts it 
into the autophagic membrane-associated LC3-II, an essential 
component for AP elongation and vesicle completion.31 In line with 
our earlier results demonstrating increased AP accumulation by 
PTP4A3 upon CQ treatment, we observed robust accumulation 
of LC3-II in CHO-PTP4A3 cells compared with CHO–Con 
and CHO-PTP4A1 cells at different time points after CQ 
treatment (Fig. 3A, red boxes) or combined treatment of CQ 
and rapamycin (Fig. 3A, blue boxes), suggesting that PTP4A3 
(but not PTP4A1) promotes both basal and rapamycin-induced 
autophagy.
To assess whether the catalytic activity of PTP4A3 was 
necessary to promote autophagic flux, the levels of LC3-I and 
II protein in A2780-Vec, A2780-PTP4A3, and A2780-PDM 
cells were analyzed. A2780-PTP4A3 cells had the highest 
autophagic flux compared with A2780-Vec and A2780-PDM 
cells under either basal (Fig. 3B, red box, lane 5) or rapamycin-
induced autophagy (Fig. 3B, blue boxes, lanes 11 and 17). 
Prenylation-defective PTP4A3 (PreΔ) similarly failed to 
recapitulate the increased autophagic flux induced by wild-type 
PTP4A3 (Fig. S2B). Consistent with our earlier observations 
on promoting AP accumulation (Fig. 2C; Fig. S2A), these 
data reaffirm that PTP4A3 requires both catalytic activity and 
prenylation to drive LC3-I to LC3-II conversion and increase 
autophagic flux. Notably, PTP4A3 could promote autophagic 
flux under starvation conditions in both CHO and A2780 cell 
lines as well (Fig. S3A and S3B).
ATG5 has been reported as a critical autophagy regulator 
which plays a role in accelerating LC3 lipidation to promote 
autophagosome elongation.32 In cells with stable ATG5 
knockdown, PTP4A3 was unable to promote LC3 conversion 
upon CQ, rapamycin, or combined CQ and rapamycin 
treatments (Fig. 3C, red boxes in lanes 2, 8, 14 vs. blue boxes in 
lanes 5, 11, 17). Taken together, our results show that PTP4A3 
promotes autophagic flux in an ATG5-dependent manner.
PTP4A3 overexpression promotes autophagic degradation 
of SQSTM1
SQSTM1 is an autophagic cargo-binding protein that is 
degraded by autophagy.33,34 Measuring SQSTM1 protein levels 
has been proposed as an alternative method for determining 
autophagic flux, with lower SQSTM1 protein expression 
indicating increased autophagy activity.35 Compared with A2780 
control cells, cells depleted of PTP4A3 expression had higher 
SQSTM1 levels (Fig. 4A, red box). Significantly, CQ treatment 
beyond 8 h effectively abolished this difference (Fig. 4B, lanes 
10 and 12), suggesting that PTP4A3 knockdown cells had lower 
autophagic flux than control cells. In contrast, we found that 
CHO-PTP4A3 cells had lower SQSTM1 levels than CHO-Con 
or CHO-PTP4A1 cells (Fig. 4C, red box, lane 3), consistent with 
a role for PTP4A3 in promoting autophagic flux. Importantly, 
inhibition of lysosomal activity using CQ reversed this phenotype 
by preventing SQSTM1 degradation in CHO-PTP4A3 cells, 
with levels now comparable to CHO-Con or CHO-PTP4A1 
cells (Fig. 4D, red box, lane 6; SQSTM1 quantification in 
right panel). Pepstatin and E64D, which are lysosomal protease 
inhibitors,36 could similarly rescue SQSTM1 levels (Fig. S4A, 
lane 3). This inverse correlation between PTP4A3 and SQSTM1 
is further evidence that PTP4A3 is able to promote autophagic 
flux.
PTP4A3 itself serves as an autophagy substrate
Unexpectedly, similar to SQSTM1, we noted that PTP4A3 
(but not PTP4A1) levels decreased dramatically in cells grown 
in amino acid-free starvation media (Hank’s balanced salt 
solution, HBSS) (Fig. 4E; red box, lane 6), a treatment that 
potently activates autophagy.1 This first indicated to us that 
PTP4A3 might be an autophagic substrate. To investigate this 
unexpected phenomenon further, we examined PTP4A3 protein 
levels in multiple cell lines upon autophagy inhibition by CQ. 
Similar to SQSTM1, CQ treatment prompted the accumulation 
of exogenous PTP4A3 in CHO-PTP4A3, A2780-PTP4A3 cells, 
and DLD1 human colorectal carcinoma cells overexpressing 
PTP4A3 (DLD1-PTP4A3) (Fig. 4F, lanes 2 and 4), as well as 
endogenous PTP4A3 in HCT116 colorectal carcinoma cells 
(Fig. 4F, lane 6) which express detectable levels of PTP4A3 
protein. In a complimentary approach, we detected increased 
levels of PTP4A3 and SQSTM1 in cells with ATG5 knockdown 
(Fig. 4G, lanes 2, 4, and 6) or BECN1 (Fig. S4B, lanes 2, 4, and 
6). These results suggest that like SQSTM1, PTP4A3 appears to 
be a bona fide autophagy-degraded protein.
Figure 2 (See opposite page). catalytically active PTP4a3 promotes aP accumulation in a PiK3c3- and BecN1-dependent manner. (A) a2780-eGFP 
(Vec), a2780-eGFP-PTP4a3 (PTP4a3), and a2780-eGFP-PTP4a3 PDM (PDM) cells were treated with cQ for 24 h before immunostaining with an anti-
Lc3 antibody. (B) Lc3 puncta intensity value of at least 20 cells from 5 distinct viewing fields were quantified as described in Materials and Methods, 
and presented as a histogram in the right panel (mean ± s.D.). (C) a2780-Vec, a2780-PTP4a3, and a2780-PDM cells were infected with stable shRNa 
knockdown constructs with either a “scrambled” sequence against non-specific targets (shscr), PIK3C3 (shPIK3C3), or BECN1 (shBECN1). The knockdown 
efficiency is shown by western blotting. (D) a2780-Vec, a2780-PTP4a3, and a2780-PDM cells were treated with cQ for 24 h, prior to analysis as in (B). 
(E) cell lines used in (D) were treated with rapamycin in combination with cQ for 4 h, prior to analysis as in (B). *P < 0.05; **P < 0.01; ***P < 0.001; Ns, P > 
0.05, not significant.
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Figure 3. catalytically active PTP4a3 promotes aTG5-dependent Lc3 conversion. (A) chO-con, chO-PTP4a1 (PTP4a1), and chO-PTP4a3 (PTP4a3) cells 
were cultured in full medium with indicated treatment for the indicated durations before lysis and western blotting analysis with the anti-Lc3 and 
anti-GaPDh antibodies. (B) a2780-Vec, a2780-PTP4a3, and a2780-PDM cells were treated as indicated, and lysed for western blotting analysis with 
antibodies against Lc3 and GaPDh antibodies. (C) a2780-Vec, a2780-PTP4a3, and a2780-PDM cells stably expressing knockdown constructs against 
nonspecific targets (shscr) or ATG5 (shATG5) were treated as indicated, and lysed for western blotting analysis with the indicated antibodies.
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Figure 4. PTP4a3 promotes sQsTM1 degradation and serves as a substrate in autophagy. (A) a2780 cells were infected with stable shRNa knockdown 
constructs against nonspecific targets (shscr) or PTP4A3 (shPTP4A3). exponentially growing a2780-shscr and a2780-shPTP4A3 cells were lysed and ana-
lyzed for stable-state sQsTM1 and PTP4a3 expression levels by western blotting. (B) a2780-shscr and a2780-shPTP4A3 cells were treated with cQ for 
indicated times before lysis and western blotting analysis of sQsTM1 expression levels. The band intensity ratio of sQsTM1/GaPDh was quantified as 
described in Materials and Methods, and presented as a histogram in the right panel (mean ± s.D.). (C) chO-con, chO-PTP4a1, and chO-PTP4a3 stable 
cells were analyzed for stable-state sQsTM1 expression levels by western blotting. (D) chO-con, chO-PTP4a1, and chO-PTP4a3 cells were cultured in 
full medium in the absence (control) or presence (cQ) of cQ for 24 h before lysis and western blot analysis of the indicated proteins. The ratio of sQsTM1/
GaPDh was quantified as described in Materials and Methods, and presented as a histogram in the right panel (mean ± s.D.). (E) chO-con, chO-PTP4a1, 
and chO-PTP4a3 cells were cultured in full media (control) or in hBss for 24 h prior to lysis and western blotting analysis of the indicated proteins. (F) 
chO-PTP4a3, a2780-PTP4a3, and hcT116 cell lines were cultured in full media in the absence (control) or presence (cQ) of cQ for 24 h prior to lysis and 
western blotting analysis of the indicated proteins. (G) ATG5 was knocked down using shRNa in a2780-PTP4a3 and hcT116 cells. exponentially growing 
cells (in full media) were lysed for western blotting analysis with the indicated antibodies. GaPDh was used as loading control.
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Taken together with our earlier results that PTP4A3 promotes 
AP formation and autophagic flux, the observation that 
PTP4A3 is also attenuated by autophagic degradation suggests 
the existence of a negative-feedback loop between PTP4A3 
Figure  5. a model illustrates the involvement of PTP4a3 in multiple steps of canonical autophagy 
pathway. 1) PTP4a3 acts as an activator to promote autophagosome formation in a PiK3c3-BecN1-
dependent manner; 2) PTP4a3 accelerates Lc3-i to Lc3-ii conversion in an aTG5-dependent manner; 
3) PTP4a3 enhances the degradation of sQsTM1, a key autophagy substrate; 4) PTP4a3 itself is a novel 
autophagic substrate. sites of action of drug treatments (rapamycin, pepstatin and e64D, cQ, Baf a1) are 
indicated at where appropriate.
and autophagy activity. Herein, we 
propose a model on how PTP4A3 
might be involved in the canonical 
autophagy pathway (Fig. 5): 1) 
PTP4A3 functions as an activator to 
promote autophagosome formation 
in a PIK3C3-BECN1-dependent 
manner; 2) PTP4A3 accelerates 
LC3-I to LC3-II conversion in 
an ATG5-dependent manner; 3) 
PTP4A3 enhances the degradation of 
SQSTM1, a key autophagy substrate; 
and 4) PTP4A3 itself serves as a 
novel autophagic substrate, fulfilling 
a negative feedback-loop to fine-tune 
autophagy activity.
PTP4A3 exploits autophagy 
to promote ovarian cancer cell 
proliferation
PTP4A3 has been shown 
to promote cancer cell growth, 
migration, invasion, angiogenesis, 
epithelial-mesenchymal transition, 
and ultimately metastasis.11 In light 
of our data suggesting that PTP4A3 
could promote autophagy, which 
in turn has established associations 
with tumor biology,9 we further 
investigated the role of autophagy 
in PTP4A3-mediated cancer 
progression. First, we compared the 
growth of A2780-Vec and A2780-
PTP4A3 cells following depletion of 
PIK3C3, BECN1, or ATG5 expression. 
Under serum-replete conditions, 
PTP4A3 promoted an increase in 
cell growth in control knockdown 
cells (shScr), as measured by MTT 
assays (Fig. 6A–C, black dashed 
lines). Importantly, knockdown of 
PIK3C3, BECN1, or ATG5 resulted 
in a significant decrease in the growth 
of A2780-PTP4A3 cells (Fig. 6A–C, 
red vs. black dashed lines; P < 
0.001). In contrast, knockdown of 
these autophagy regulators had no 
significant effect on A2780-Vec cell 
growth (Fig. 6A–C, red vs. black 
solid lines; P > 0.05), consistent with 
a previous report demonstrating 
that A2780 cells are insensitive to 
autophagy inhibition under serum-
replete conditions.37 We next repeated and measured the growth 
of these cells under serum starvation, a common autophagy 
inducer in cultured cells.1 Interestingly, under serum starvation, 
A2780-PTP4A3 cells could survive and grow for up to 4 d, with 
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knockdown of PIK3C3, BECN1, or ATG5 resulting in reduced 
growth (Fig. 6D–F, red vs. black dashed lines; P < 0.001). In 
contrast, A2780-Vec cells were unable to grow under serum- 
starved conditions (Fig. 6D–F, red vs. black solid lines; P > 0.05). 
Collectively, these results suggest that PTP4A3 promotes ovarian 
cancer cell growth and survival via an autophagy-dependent 
mechanism, a particularly important manifestation under serum 
starvation stress.
Figure  6. Overexpression of PTP4a3 promotes cell proliferation in a2780 cells in an autophagy-dependent manner. (A–C) a2780-vec and a2780-
PTP4a3 cells infected with shscr or shPIK3C3 (A), shBECN1 (B), or shATG5 (C) were cultured in full media. Relative proliferation rates were measured using 
an MTT assay. (D and E) cell lines used in (A–C) were cultured in serum-free RPMi media. Relative proliferation rates were measured using an MTT assay. 
(G and H) a2780-Vec and a2780-PTP4a3 cells were cultured in full media (G) or serum-free (H) in the absence (control) or presence of cQ. a representa-
tive relative proliferation rate curve is shown. similarly treated cells were analyzed (48 h treatment) in parallel by western blotting for paKT, total aKT, 
Lc3, sQsTM1, and hsPD1 levels (right panel).
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Next, we inhibited lysosomal degradation with CQ. We 
observed a significant decrease in growth of both A2780-
Vec (Fig. 6G, red vs. black solid lines; P < 0.001) and A2780-
PTP4A3 cells (Fig. 6G, red vs. black dashed lines; P < 0.001) 
upon CQ treatment under serum-replete conditions. Critically, 
the enhanced cell growth induced by PTP4A3 overexpression 
was effectively abolished by CQ treatment alone, suggesting that 
cells harboring increased PTP4A3 expression are more sensitive 
to autophagy inhibitors.
PTP4A3 overexpression promotes AKT activity by 
phosphorylation (pAKT) on Ser473 of the kinase.11,38 In A2780-
PTP4A3 cells grown in serum-replete conditions, we detected 
increased pAKT compared with A2780 control cells (Fig. 6G, 
right panel, lanes 1–2). Moreover, treatment with CQ caused 
pAKT levels to decrease in A2780-PTP4A3 cells, but not in 
A2780-Vec cells (Fig. 6G, right panel, lanes 3 and 4). Under 
serum-depleted conditions, A2780-PTP4A3 cells were also able 
to survive and continue growth despite the absence of serum and 
glutamine supplementation, whereas A2780 control cells could 
not (Fig. 6H, black lines; P < 0.001). Importantly, CQ treatment 
abolished the difference in growth rate between A2780-Vec 
and A2780-PTP4A3 cells (Fig. 6H, red lines; P > 0.05). Since 
PTP4A3 overexpression has been shown to promote pAKT levels 
under growth-factor deprived conditions,39 we tested whether 
AKT activity was similarly involved in the ability of PTP4A3 
to sustain cell growth under serum-starved conditions. Indeed, 
under serum-free conditions, relative to control cells, A2780-
PTP4A3 cells were able to sustain pAKT levels to a greater 
extent than A2780-Vec cells (Fig. 6H, western blot lanes 1 and 
2). Importantly, CQ treatment reduced the difference in pAKT 
levels between these 2 cell lines (Fig. 6H, western blot lanes 3 and 
4), thereby uncoupling PTP4A3-dependent pAKT signaling. 
Taken together, our data suggests that PTP4A3 overexpression 
increased autophagy activity and thus endowed cells with a growth 
advantage regardless of growth factor availability—an advantage 
that can be effectively suppressed by autophagy inhibition.
High expression levels of PTP4A3 predict poorer survival of 
ovarian cancer patients coexpressing high levels of autophagy 
genes
To investigate the clinical relevance of our in vitro findings 
obtained from CHO and A2780 ovarian cell lines, we extracted 
microarray and clinical-pathological data from an ovarian cancer 
patient cohort (GSE 9899), the largest ovarian cancer data set (n = 
285) currently available in the GEO database. In agreement with 
previous studies showing that PTP4A3 overexpression promotes 
ovarian cancer progression,40 we found that mRNA expression of 
Figure 7. high PTP4a3 expression levels predict poorer survival of ovarian cancer patients coexpressing high levels of autophagy genes in the Gse9899 
patient cohort. (A) in ovarian cancer patients with high levels of PIK3C3, PTP4A3 expression levels were significantly correlated with higher pathological 
stage. (B) Patients with high expression levels of PIK3C3 and PTP4A3 have significantly reduced recurrence-free survival. (C and D) similar results as in (A 
and B) were obtained when the tumors were stratified by BECN1 instead of PIK3C3.
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PTP4A3 was significantly increased in malignant ovarian tumors 
compared with those with low malignant potential tumors 
(Fig. S5A; P < 0.001). Increased PTP4A3 mRNA expression was 
associated with both higher histological grade 2 and 3 (Fig. S5B; 
P = 0.001) and pathological stage IV (Fig. S5C; P = 0.006). 
Moreover, a higher level of PTP4A3 mRNA was significantly 
associated with a shorter survival time in this ovarian cancer 
patient cohort (Fig. S5D; P = 0.007, Kaplan-Meier analysis, log-
rank test). By Cox-regression analysis, increasing expression of 
PTP4A3 mRNA was significantly associated with higher risk of 
recurrence-associated death (P = 0.009; HR = 1.223, 95% CI = 
1.051–1.424). Thus, ovarian cancer patients having low PTP4A3 
expression did profoundly better than those having high levels of 
PTP4A3, supporting the oncogenic character of PTP4A3.
To investigate whether autophagy contributed to the 
prognostic significance of PTP4A3 in this ovarian cancer patient 
cohort, we then stratified patients into “high” or “low” groups 
using the median mRNA expression of PIK3C3 and BECN1 as 
cut-off points. Neither PIK3C3 nor BECN1 individually had 
significant prognostic value on patient survival using this cut-
off criterion (Fig. S6A and S6B). Nonetheless, in patients with 
high PIK3C3 mRNA expression, PTP4A3 mRNA expression 
was significantly associated with pathological stage III and 
IV (Fig. 7A; P = 0.002) and patient recurrence-free survival 
(Fig. 7B; P = 0.003). In contrast, in patients with low PIK3C3 
mRNA expression, PTP4A3 mRNA level was not significantly 
associated with any of these clinical-pathological parameters 
(Fig. S7A and S7B). Similar results were obtained when BECN1 
mRNA expression was used to stratify the patients. In patients 
with high BECN1 expression, PTP4A3 mRNA expression was 
significantly associated with pathological stage IV (Fig. 7C; P = 
0.003) and shorter recurrence-free survival (Fig. 7D; P = 0.001). 
Intriguingly, in patients with low BECN1 expression, PTP4A3 
expression was again not significantly associated with any of 
these clinical pathological parameters (Fig. S7C and S7D). 
Significantly, Cox-regression analysis revealed that increasing 
mRNA expression of PTP4A3 was significantly associated with a 
higher risk of recurrence-associated death only in patients with a 
high level of PIK3C3 (Table S1) or BECN1 (Table S2) expression.
Discussion
In this study, we demonstrated that metastasis-associated 
PTP4A3 phosphatase functions as an activator of canonical 
autophagy and also serves as a substrate for canonical autophagy. 
Autophagy inhibition effectively curtailed PTP4A3-driven cell 
growth, as well as its ability to enhance AKT phosphorylation. 
We showed that autophagy plays an important role in PTP4A3-
mediated ovarian cancer progression and, more importantly, 
characterized how the prognostic significance of PTP4A3 
correlates with high expression levels of various autophagy-
related genes in clinical patient samples. Taken together, our 
results indicate that autophagy inhibition represents an attractive 
therapeutic approach against ovarian cancers having high 
expression of both PTP4A3 and autophagy genes.
Our results provide evidence that PTP4A3, but not PTP4A1, 
localizes to autophagosomes and promotes autophagy. This is 
surprising, given that these 2 phosphatases share 78% amino 
acid sequence identity and are both endosomally localized.9 In 
agreement with autophagosomal localization, we report here that 
overexpressed PTP4A3, but not PTP4A1, could be degraded via 
autophagy. Importantly, this applies for endogenous PTP4A3 
as well, suggesting that autophagic degradation of PTP4A3 
was not simply due to nonspecific aggregation of overexpressed 
protein.41 Such specificity potentially sets the stage for a highly 
tuned feedback mechanism by PTP4A3 on canonical autophagic 
activity—as PTP4A3 levels accumulate, autophagy flux is 
enhanced and consequently becomes degraded by autophagy, 
thereby eventually returning autophagy activity to a homeostatic 
functional state. Indeed, PTP4A3 is not the only autophagy-
regulated protein with such a feedback role on autophagy. The 
essential autophagy core component and regulator ULK1/ATG1 
has recently been reported as an autophagy substrate, similarly 
constituting a negative feedback loop believed to play a role in 
the maintenance of balanced autophagic activity.42 Such negative 
feedback loops might serve to prevent autophagic cell death as 
a consequence of unrestricted autophagic activity which would 
result in progressive consumption of cellular components and 
subsequent autophagic cell death.43 Our findings here suggest 
a role for PTP4A3 in balancing autophagy activity in nutrient-
demanding cancer cells under starvation conditions, where 
nutrient recycling via autophagy might be critical to tolerate such 
stress and protect cells from apoptosis.44
Herein, we show that PTP4A3 promotes PIK3C3-, BECN1-, 
and ATG5-dependent canonical autophagy. Suppression of these 
critical autophagy regulators or treatment with CQ inhibited 
autophagy flux in ovarian cancer cells and effectively crippled the 
ability of PTP4A3 to drive cell proliferation. The physiological 
importance of this is that PTP4A3 requires functional autophagy 
to promote ovarian cancer proliferation. Clinical data supports 
this—we show that the prognostic effect of PTP4A3 in human 
ovarian cancers is significant in cases where there is a genetic 
background with elevated autophagy-related gene (BECN1, 
PIK3C3, and ATG5) expression. Recently, activated KRAS 
was shown to increase cancer cell dependence on autophagy 
for survival and tumorigenesis.43 Interestingly, there are several 
parallels between PTP4A3 and KRAS: 1) both PTP4A3 
expression and KRAS activity increases in more aggressive 
cancers; 2) autophagy activation by PTP4A3 or KRAS is critical 
to allow cancer cell proliferation under starvation conditions; 
and, 3) both potentiate receptor tyrosine kinase signaling. 
Intriguingly, RAS and PTP4A3 also share similar membrane-
targeting modules—a polybasic motif and prenylation—in their 
carboxy termini domains, presumably localizing them in close 
proximity on cellular membranes.
To translate our in vitro findings into a more clinically relevant 
context, we investigated the survival outcomes of ovarian cancer 
patients with high or low PTP4A3 and autophagy-related genes 
mRNA expression levels. We found that in the presence of high 
autophagy gene expression, patients coexpressing high levels of 
PTP4A3 mRNA had significantly shorter survival than patients 
D
ow
nl
oa
de
d 
by
 [9
2.1
3.2
33
.48
] a
t 0
3:1
4 1
8 M
arc
h 2
01
6 
©
20
14
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
1798 autophagy Volume 10 issue 10
coexpressing low levels of PTP4A3 mRNA. In light of our in 
vitro data suggesting that PTP4A3 is dependent on the autophagy 
pathway for cancer progression, we propose that inhibition of 
autophagy might effectively block the oncogenic functions of 
PTP4A3 in such patient tumors. Currently, autophagy inhibition 
is at the forefront of cancer therapy, with approximately 20 
ongoing clinical trials in multiple types of cancers.47 In view of 
our current understanding of the molecular factors that determine 
the opposing roles of autophagy during cancer progression, the 
identification of PTP4A3 as a candidate biomarker to predict 
the favorable response to autophagy inhibition is envisioned 
to have significant clinical utility. This is especially pertinent, 
given that drugs that result in either autophagy activation or 
inhibition have been demonstrated to provide therapeutic value 
in combating cancers, highlighting the essential need for proper 
patient diagnostics and stratification prior to treatment. Recent 
research has shown that some cancer cells—such as those driven 
by active KRAS—depend upon and get addicted on elevated 
levels of autophagy for survival even in the absence of external 
stressors.47 In view of this, we propose that the targeted inhibition 
of autophagy in PTP4A3-positive tumors might be a significant 
advancement in developing a novel therapeutic approach for 
treating similarly “autophagy-addicted” ovarian tumors due to 
overexpression of both PTP4A3 and autophagy genes.
Materials and Methods
Cell culture conditions
CHO-K1 cells (ATCC), human ovarian carcinoma cell line 
A2780 (ATCC), and human colorectal carcinoma cell line HCT116 
(ATCC) were maintained in RPMI-1640 medium supplemented 
with 10% fetal bovine serum (HyClone, SV30160.03), 2 mM 
L-glutamine (Life Technologies, 25030-081), and 1% antibiotic/
anti-mycotic (Life Technologies, 15140-122) (“full media”). 
Where indicated, cells were starved in the absence of serum 
(“serum free”) or HBSS. The viral packaging cell line Phoenix 
Ampho (a gift from the Nolan Laboratory, Stanford University) 
and 293T cells (ATCC) were maintained in DMEM 4.5 g/L high-
glucose medium supplemented with 10% fetal bovine serum, 2 
mM L-glutamine, and 1% antibiotic/antimycotic. All cells were 
maintained in a 5% CO
2
 atmosphere at 37 °C.
Plasmids and transfection
CHO-PTP4A1, CHO-PTP4A3, and CHO-EGFP-PTP4A3 
cells were generated previously.13 A2780-Vec, A2780-PTP4A3, 
and A2780-PTP4A3-PDM cells were generated from A2780 
parental cells (ATCC), and the plasmids used including 
pEGFPC1 vector, pEGFP-PTP4A3, and pEGFP-PTP4A3-PDM 
were generated previously.14 Lentiviral-mediated knockdown of 
PIK3C3, BECN1, ATG5, and PTP4A3, (Mission shRNA, Sigma-
Aldrich) was performed as previously described.48 Transfection 
was done using JetPRIME according to the manufacturer’s 
instructions (Polyplus-transfection, 114-75).
Reagents
Unless otherwise specified, chemicals were used at the 
following final concentrations; chloroquine diphosphate salt (50 
μM, C6628, Sigma-Aldrich); rapamycin (2 μM, R8781, Sigma-
Aldrich); E64D (10 μg/ml, E8640, Sigma-Aldrich); pepstatin 
A (10 μg/ml, P5318, Sigma-Aldrich); bafilomycin A
1
 (100 nM, 
B1793, Sigma-Aldrich). HBSS (phenol red-free; 14025-126) was 
purchased from Life Technologies.
Immunofluorescence staining
Immunofluorescence staining was done as described 
previously.48 Briefly, cells were fixed in 4% formaldehyde for 15 
min, washed with PBS, and then permeabilized and blocked with 
0.3% Triton X-100 (BDH Chemicals, 9002-93-1) and 5% BSA 
(Sigma-Aldrich, 05470), respectively, for 1 h. Cells were then 
incubated with primary antibodies overnight at 4 °C. Anti-LC3 
antibody (3868, Cell Signaling Technology) was used at a dilution 
of 1:200 and PTP4A3 antibody49 was used at a dilution of 1:400. 
Cells were then washed thrice with PBS and then incubated with 
secondary antibody (1:400 dilution; Life Technologies, A10040, 
A10036) conjugated with appropriate fluorophore for 1 h at 
room temperature. Slides were mounted with Prolong Gold Anti-
fade Reagent and staining was analyzed immediately using an 
LSM700 confocal microscope (Carl Zeiss AG). The average LC3 
channel pixel intensity value within the cytoplasmic area per cell 
was determined using Photoshop (Adobe Systems) to represent 
the overall amount of LC3 puncta accumulation in each cell. The 
colocalzation percentage of LC3 puncta with PTP4A3 puncta 
was counted using visual inspection. The results were presented 
as mean ± SD.
Western blotting
Western immunoblotting was performed as previously 
described.48 BECN1 (3495), LC3 (3868), ATG5 (8540), 
SQSTM1 (5114), phospho-AKT-Ser473 (4060), and AKT 
(4691) were purchased from Cell Signaling Technology. 
GAPDH (MAD372) was purchased from Millipore. HSPD1 
(611562) antibody was purchased from BD Biosciences. PTP4A1 
and PTP4A3 antibodies were generated in-house.49 Anti-
rabbit HRP-labeled secondary antibody (7074) was purchased 
from Cell Signaling Technology, and anti-mouse HRP-labeled 
secondary antibody (115-035-003) was purchased from Jackson 
ImmunoResearch Laboratories. Immunoreactive bands were 
visualized using chemiluminescent substrate (Thermo Scientific, 
34080) and detected on radiography film. Quantification of 
band intensity was done using ImageJ software.
MTT cell proliferation assay
A2780 cells were seeded at a concentration of 5,000 cells per 
well in 96-well plates in triplicate. Cells were allowed to grow 
for 24 h and the medium was replaced with desired media with 
or without drugs, as indicated. MTT reagent (M5655, Sigma-
Aldrich) was added at a final concentration of 0.2 mg/mL in 
each well. Cells were incubated with MTT reagent at 37 °C for 
3 h. Medium was completely removed and the retained formazan 
crystals were then dissolved in DMSO and the absorbance at 
595 nm was measured.
Analysis of ovarian cancer patient microarray data
The GEO-accessible GSE9899 data set consisting of 285 
ovarian cancer patients with corresponding microarray, clinic-
pathological, and survival data was used in this study. This is 
the largest ovarian cancer cohort data set available in the GEO 
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database. Microarray and patient data were extracted as previously 
described.48 Patients were divided into 4 subgroups, including 
weak, moderate, strong, and very strong, based on their PTP4A3 
mRNA expression levels using quartiles as the cut-off point. 
The highest quartile of PTP4A3 was used as a cut-off point to 
separate patients into high and low subgroup for Kaplan-Meier 
survival analysis. The association between PTP4A3 expression 
and clinical-pathological parameters was tested by Chi-Square, 
while the association between PTP4A3 and patient survival 
was tested by Kaplan-Meier analysis together with log-rank 
test. Patients were further stratified based on their PIK3C3 and 
BECN1 mRNA expression levels using the median value as a cut-
off point to distinguish a more autophagy-competent subgroup 
(“high”) and a less autophagy-competent subgroup (“low”).
Statistical analysis
All the statistical analyses were performed using SPSS19.0 
software (IBM Corporation). One-way ANOVA was performed 
for comparison of means between groups. Repeated measures 
ANOVA was performed for MTT assay where data was obtained 
at multiple time points. The P value for comparison of 2 groups 
in the same experimental setting was generated by ANOVA post-
hoc test, either Tukey HSD or Games-Howell, depending on 
the results from the homogeneity test by Levene statistics, where 
applicable. A P value of < 0.05 was considered as significant in 
all tests.
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